International MIGS Study Confirms Long-Term Safety and Efficacy of the OMNI® Surgical System Predicate Device (VISCO360®)

OCTOBER 22, 2019

Sight Sciences, Inc., today announced a new, single center study of glaucoma surgery patients published in the July 2019 issue of Clinical Ophthalmology, which shows that ab-interno microcatheterization and 360˚ viscodilation of Schlemm’s Canal using one of the OMNI® Surgical System’s predicate devices (VISCO360®) provides a favorable safety profile and substantial long-term reductions in both 
+ Read More


First International MIGS Data for the OMNI® Surgical System Presented at ESCRS

SEPTEMBER 21, 2019

Sight Sciences announced clinical results from the first study of the OMNI® Surgical System in glaucoma patients were presented at the European Society of Cataract and Refractive Surgery (ESCRS). Findings from the pilot study suggest the OMNI® Surgical System, which is dually indicated in Europe for the sequential ab interno procedures of microcatheterization and transluminal 
+ Read More


Sight Sciences Raises $56M of Growth Capital to Lead the Development of the Standalone MIGS Market and Procedure-Based Dry Eye Market

SEPTEMBER 04, 2019

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced the closing of $31 million in Series D Preferred Stock financing led by KCK Group, a leading investor in high growth medical technology companies. MidCap Financial, a prominent middle-market lender 
+ Read More


Sight Sciences Hires Leading Industry Executives to Drive Continued Growth

AUGUST 07, 2019

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced that Jessica Holmes, Brian Regan and Jim Sluck have joined the company as Vice President of Health Policy & Reimbursement, Vice President of Strategy & Professional Relations and Vice President 
+ Read More


First Subject Enrolled in large, multi-center pivotal trial to confirm safety and efficacy of TearCare® in the treatment of signs and symptoms of Dry Eye disease

JUNE 13, 2019

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye, today announced the first subject has been enrolled in OLYMPIA, the U.S. pivotal trial to further assess the safety and efficacy of TearCare® for patients with dry eye disease. TearCare® is the only 
+ Read More


Sight Sciences Announces Official Launches of TearCare® and the Enhanced, Next Generation OMNI® System

APRIL 30, 2019

New Dry Eye and MIGS Entrants will be Prominently Featured in Product Demonstrations and Events at Upcoming Industry Shows MENLO PARK, Calif. – Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry – dry eye and glaucoma – today announced the official commercial launch of TearCare® 
+ Read More


First Subjects Enrolled in Clinical Study to Evaluate Safety and Efficacy of OMNI™ Surgical System for Multiple Micro-Invasive Glaucoma Surgery Procedures

MARCH 27, 2019

MENLO PARK, Calif. – Sight Sciences today announced enrollment has begun in the Gemini clinical study, a Sight Sciences-sponsored, prospective, multi-center study to evaluate the safety and efficacy of the OMNI™ Surgical System in performing two sequential Micro-Invasive Glaucoma Surgery (MIGS) procedures – transluminal viscoelastic delivery and trabeculotomy. Subjects must have mild-to-moderate primary open angle 
+ Read More


Clinical Study Demonstrates Long Term IOP Reduction With The OMNI® Surgical System Predicate Device (TRAB®360) In Micro-Invasive Glaucoma Surgery

MARCH 14, 2019

A new, single center retrospective study of glaucoma surgery patients published in the January 2019 issue of Clinical Ophthalmology shows that ab-interno trabeculotomy using one of Sight Sciences’ OMNI® Surgical System’s Predicate Devices (TRAB®360) provides a favorable safety profile and substantial long-term reductions in both intraocular pressure (IOP) and IOP-lowering medications. Conducted by Steven Sarkisian, 
+ Read More


Retreatment With A Single TearCare® Treatment Continues To Provide Relief For Patients With Dry Eye Disease

FEBRUARY 12, 2019

A new, single center, prospective clinical study published in the January issue of Clinical Ophthalmology provides preliminary evidence that retreatment with the Sight Sciences TearCare System is a safe and effective treatment for dry eye disease, according to a company news release.  The TearCare System is indicated for use in meibomian gland dysfunction (MGD), dry eye, and 
+ Read More


Reay H. Brown, M.D., Joins Sight Sciences as Chief Medical Officer

OCTOBER 23, 2018

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye treatment, today announced Reay H. Brown, M.D., has joined the company as Chief Medical Officer (CMO). Dr. Brown is one of the most prolific inventors and innovators in the history of surgical glaucoma.  
+ Read More